Lack of signaling by IL-4 or by IL-4/IL-13 has more attenuating effects on Leishmania amazonensis dorsal skin--than on footpad-infected mice.
Lesion development in tegumentary leishmaniasis is markedly influenced by the inoculation site and the type and number of injected infective forms. This and the yet unclear contribution of Th2 cytokines as susceptibility factors to Leishmania amazonensis infection prompted us to investigate the roles of IL-4, IL-13 and IL-10 on C57BL/6 and BALB/c mice infected in the footpad (paw) or rump with low-dose L. amazonensis purified-metacyclics. Wild-type (WT) mice of either strain developed, in the rump, a single large ulcerated lesion whereas paw lesions never ulcerated and were much smaller in C57BL/6 than in BALB/c mice. However, rump-inoculated IL-4-deficient (IL-4(-/-)) C57BL/6 mice did not develop any visible lesions although parasites remained in the dermis and lymph nodes, even after systemic IL-10-receptor blocking. By comparison, all IL-4(-/-) BALB/c mice developed rump ulcers. Strikingly, only 30% of rump-infected IL-4Rα(-/-) BALB/c mice developed lesions. IL-4(-/-) mice had higher IFN-γ and lower IL-10 and IL-13 levels than WT mice. Paw-infected IL-4Rα(-/-) BALB/c mice developed minimal paw lesions. While other factors contributing to L. amazonensis susceptibility cannot be discounted, our results indicate that absent signalling by IL-4 or by IL-4/IL-13 have more intense attenuating effects on rump than on paw lesions but do not eradicate parasitism.
Departamento de Imunologia, Instituto de Ciências Biomédicas IV, Universidade de São Paulo, Av Prof Lineu Prestes 1730, 05508-900 São Paulo, Brazil. tania.felizardo@nih.gov
Tania C
TC
Felizardo
Maria I C
MI
Gaspar-Elsas
Gloria M C A
GM
Lima
Ises A
IA
Abrahamsohn
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D001415:Back; D005260:Female; D005528:Foot / Q000469:parasitology / Q000473:pathology; D018793:Interleukin-13 / Q000502:physiology*; D015847:Interleukin-4 / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D007894:Leishmania mexicana / Q000276:immunology* / Q000502:physiology; D016773:Leishmaniasis, Cutaneous / Q000276:immunology*; D008198:Lymph Nodes / Q000276:immunology / Q000469:parasitology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D011956:Receptors, Cell Surface / Q000172:deficiency / Q000235:genetics; D053701:Receptors, Interleukin-10 / Q000276:immunology; D015398:Signal Transduction / Q000502:physiology*; D012867:Skin / Q000469:parasitology / Q000473:pathology; D013154:Spleen / Q000469:parasitology; D053662:Interleukin-4 Receptor alpha Subunit
D000911:Antibodies, Monoclonal; D018793:Interleukin-13; D015847:Interleukin-4; D011956:Receptors, Cell Surface; D053701:Receptors, Interleukin-10; C504002:Il4ra protein, mouse; D053662:Interleukin-4 Receptor alpha Subunit